10-Q: Scholar Rock Announces Positive Top-Line Results from Phase 3 SAPPHIRE Trial and Provides Q3 2024 Financial Update

Scholar Rock reports positive results from its Phase 3 SAPPHIRE trial for apitegromab in SMA and provides a financial update for the third quarter of 2024.

Summary

• Scholar Rock announced positive top-line results from its Phase 3 SAPPHIRE clinical trial for apitegromab in patients with spinal muscular atrophy (SMA).
• The trial met its primary endpoint, showing a statistically significant improvement in motor function compared to placebo.
• The company plans to submit a Biologics License Application (BLA) to the FDA and a marketing authorization application to the EMA in Q1 2025.
• Scholar Rock also completed enrollment in the Phase 2 EMBRAZE trial for apitegromab in obesity, with top-line results expected in the second quarter of 2025.
• The company reported a net loss of $179.8 million for the nine months ended September 30, 2024, and had an accumulated deficit of $856.3 million.
• Research and development expenses increased to $134.2 million for the nine months ended September 30, 2024, driven by clinical trial costs and manufacturing.
• The company completed a follow-on offering in October 2024, raising approximately $324.4 million in net proceeds.
• Scholar Rock believes its existing cash, cash equivalents, and marketable securities, along with the proceeds from the recent offering, will fund operations through at least one year after the financial statements are issued.

Sentiment

Score: 8

Explanation: The document is highly positive due to the successful Phase 3 trial results and the substantial capital raise. However, the company's ongoing losses and reliance on future funding temper the overall sentiment slightly.

Positives

• The SAPPHIRE trial results are a significant milestone for apitegromab's development in SMA.
• The completion of enrollment in the EMBRAZE trial marks progress in the company's expansion into cardiometabolic disorders.
• The successful follow-on offering provides substantial funding to support ongoing operations and development programs.
• The company has a long-term extension study, ONYX, for patients from both the TOPAZ and SAPPHIRE studies, who are receiving apitegromab in conjunction with an approved SMN therapy.

Negatives

• The company has incurred significant net losses since inception, including a $179.8 million loss for the nine months ended September 30, 2024.
• Research and development expenses are substantial and expected to remain high as clinical programs progress.
• The company has not generated any revenue from product sales to date.
• The company is reliant on third-party manufacturers for its product candidates.

Risks

• Clinical trials may not be successful, and regulatory approvals may be delayed or not received.
• The company relies on third parties for manufacturing and clinical trial execution, which could lead to delays or quality issues.
• The company may face challenges in commercializing its products, including building sales and marketing capabilities.
• The company may need to raise additional capital in the future to fund its operations.
• The company is subject to risks associated with the biopharmaceutical industry, including competition, intellectual property protection, and regulatory compliance.
• The company is subject to risks associated with global economic and political developments, including rising inflation and capital market disruptions.

Future Outlook

The company expects its existing cash, cash equivalents, and marketable securities, along with the proceeds from the recent offering, will fund operations into the fourth quarter of 2026. They plan to submit regulatory applications for apitegromab in Q1 2025 and launch the product in the U.S. in Q4 2025, with a European launch to follow. Top-line results from the EMBRAZE trial are expected in Q2 2025.

Management Comments

• The company announced positive top-line data from our Phase 3 SAPPHIRE clinical trial evaluating the efficacy and safety of apitegromab.
• The study achieved its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement for apitegromab compared to placebo in motor function.
• We are planning to submit a U.S. Biologics License Application to the FDA and a European Union marketing authorization application to the EMA in Q1 2025.
• We are also continuing our long-term extension study, ONYX, for patients from both the TOPAZ and SAPPHIRE studies, who are receiving apitegromab in conjunction with current standard of care.

Industry Context

This announcement is significant in the context of the SMA treatment landscape, as apitegromab is being developed as a potential first muscle-targeted therapy. The expansion into cardiometabolic disorders with SRK-439 also reflects a broader trend in the biopharmaceutical industry to explore new therapeutic areas.

Comparison to Industry Standards

• The positive results from the Phase 3 SAPPHIRE trial are comparable to or better than results seen in other late-stage SMA trials, such as those for Spinraza and Evrysdi, which have shown improvements in motor function.
• The 1.8 point mean difference in HFMSE is clinically meaningful and suggests a potential benefit for patients with nonambulatory Type 2 and Type 3 SMA.
• The company's expansion into cardiometabolic disorders with SRK-439 is similar to other companies exploring new indications for existing or novel therapies, such as Novo Nordisk and Eli Lilly in the obesity space.
• The company's cash runway into the fourth quarter of 2026 is relatively strong compared to other companies at a similar stage of development, but will require additional capital to complete clinical development and commercialization.

Stakeholder Impact

• Shareholders will benefit from the positive clinical trial results and the company's strengthened financial position.
• Patients with SMA may have a new treatment option if apitegromab receives regulatory approval.
• Employees will continue to be involved in the development and commercialization of the company's product candidates.
• The company's suppliers and partners will continue to play a role in the manufacturing and distribution of its products.

Next Steps

• Submit a Biologics License Application (BLA) to the FDA and a marketing authorization application to the EMA in Q1 2025.
• Continue the long-term extension study, ONYX, for patients from both the TOPAZ and SAPPHIRE studies.
• Analyze and present data from the Phase 2 EMBRAZE trial in Q2 2025.
• Prepare for the commercial launch of apitegromab in the U.S. in Q4 2025, followed by a European launch.

Key Dates

Keywords

apitegromab, spinal muscular atrophy, SMA, clinical trial, Phase 3, SAPPHIRE, FDA, EMA, regulatory approval, biopharmaceutical, SRK-181, SRK-439, cardiometabolic disorders, obesity, monoclonal antibody, myostatin, TGF, cancer, immunotherapy, financial results, follow-on offering